CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million

Stock News

03/31

CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.

According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1134093030"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134093030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134093030?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 01:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134093030","market":"other","top_or_hot":-1,"title":"CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million","media":"Stock News","content":"<p>CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.</p>\n<p>According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-31 01:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.</p>\n<p>According to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02592","symbol_name":"撥康視雲-B","start_time":0,"source_url":"","article_id":"1134093030","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134093030","pubTimestamp":1774892659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02592":"拨康视云-B","BK1161":"生物科技"},"translate_title":"CLOUDBREAK-B报告年度亏损收窄6766万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02592":1},"content_text":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04% year-on-year. The net loss was $67.66 million, narrowing by 31.75% compared to the previous year. The basic loss per share was $0.10.\nAccording to the announcement, subject to regulatory approval, the company anticipates launching CBT-001 in the US market within approximately four years, by 2030. Concurrently, the company will evaluate commercialization strategies while maximizing the potential of its proprietary technology and assets as part of its portfolio. Given the large patient population for pterygium and conjunctival hyperemia and the limited market competition, the company expects significant market opportunities and considerable revenue potential for CBT-001 following its market launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}